Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21409056 | 0.98 | HPGD (0.57) | HPGDALDH1A1TSHRLMNAGRM5 | |
| SCHEMBL18485328 | 0.94 | HPGD (0.69) | HPGDALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL1299273 | 0.92 | HPGD (0.65) | HPGDALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL1299272 | 0.92 | HPGD (0.65) | HPGDALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL1299276 | 0.92 | HPGD (0.65) | HPGDALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL18485319 | 0.84 | EPHX2 (0.51) | HPGDALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL3706273 | 0.83 | HPGD (0.86) | HPGDALDH1A1TSHRLMNAGRM5 | |
| SCHEMBL12714626 | 0.83 | HPGD (0.86) | HPGDALDH1A1TSHRLMNAGRM5 | |
| SCHEMBL700845 | 0.82 | HPGD (0.83) | HPGDALDH1A1TSHRLMNAGRM5 | |
| SCHEMBL700843 | 0.82 | HPGD (0.83) | HPGDALDH1A1TSHRLMNAGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878981-B2 | Method for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20170121286-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3130581-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121286-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | REN, AGT, AGTR1 | HPGD 589/4885ALDH1A1 149/4885TSHR 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.